eDyNAmiC: Understanding extrachromosomal DNA in cancer
Official title: eDyNAmiC - SCRIPPS
Funded at Scripps Research Institute, the · NIH-11539605 · Data updated 2026-11-12
A study at Scripps aims to understand how circular ecDNA in cancer drives aggressive tumors and how we might target it to help patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | June 24, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $658,783 |
| NIH project number | 3OT2CA278692-01S4 |
| Project ID | NIH-11539605 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients whose tumors harbor ecDNA or are believed to have ecDNA-positive cancers.
✕Less likely to help
Patients with cancers not driven by ecDNA may see limited or no direct benefit from this research.
What this research studies
This project focuses on how extrachromosomal DNA circles in cancer cells boost cancer-causing genes and help tumors evolve and resist treatment. Researchers will combine clinical insights with interdisciplinary methods to map ecDNA formation, regulation, and movement inside cells. The goal is to uncover vulnerabilities in ecDNA-containing cancers that could lead to new strategies for therapy and improved patient outcomes.
Why it matters
Potential benefit: If successful, findings could lead to new ways to treat ecDNA-driven cancers and extend survival for patients with aggressive tumors.
How similar studies have gone: Previous work has shown ecDNA presence is linked to aggressive cancer and treatment resistance, suggesting potential for targeted strategies.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Cravatt, Benjamin F — Scripps Research Institute, the
- Study coordinator: Cravatt, Benjamin F
Related research
Other NIH-funded projects on the same topics.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.